Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782253 | 0.79 | MAPT (0.53) | MAPTGPR84TLR8ALOX15ELANE | |
| SCHEMBL2799525 | 0.75 | TLR8 (0.39) | MAPTGPR84TLR8ALOX15ELANE | |
| SCHEMBL7796046 | 0.68 | ALOX15 (0.47) | MAPTTLR8ALOX15SRCSTS | |
| SCHEMBL2802740 | 0.68 | MAPT (0.45) | MAPTGPR84TLR8ALOX15ELANE | |
| SCHEMBL7895255 | 0.66 | PTGS2 (0.56) | MAPTGPR84SMN1; SMN2KMT2APTGS2 | |
| SCHEMBL28579097 | 0.66 | PTGS2 (0.56) | MAPTGPR84SMN1; SMN2KMT2APTGS2 | |
| SCHEMBL3923901 | 0.66 | MAPT (0.42) | MAPTTLR8ALOX15ELANESIRT2 | |
| SCHEMBL30889347 | 0.66 | MAPT (0.42) | MAPTTLR8ALOX15ELANESIRT2 | |
| SCHEMBL10828996 | 0.66 | MAPT (0.47) | MAPTGPR84TLR8ALOX15ELANE | |
| SCHEMBL9603284 | 0.66 | MAPT (0.37) | MAPTTLR8ALOX15ELANESRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485377-B9 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-2174939-A1 | Pyranones useful as ATM inhibitors | Kudos Pharmaceuticals Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| EP-1485377-B1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-7049313-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LTD. (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1485377-A1 | PYRANONES USEFUL AS ATM INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-20040002492-A1 | Induce immunology response; anticancer agents | KUDOS PHARMACEUTICALS LTD (GB) | 2004-01-01 | — | — | US | disclosed |
| WO-2003070726-A1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARMACEUTICALS LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002492-A1 | Induce immunology response; anticancer agents | MYD88, IFNG, HCCS | MAPT 4832/4885GPR84 3071/4885TLR8 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.